MedTrace Logo

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT04162769 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2022-11-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderate-to-severe atopic dermatitis (AD).

Conditions

Interventions

DRUG

Etrasimod 1 mg

Etrasimod 1 mg tablet taken by mouth, once daily

DRUG

Etrasimod 2 mg

Etrasimod 2 mg tablet taken by mouth, once daily.

DRUG

Etrasimod matching placebo

Etrasimod matching placebo tablet by mouth, once daily.

Sponsors & Collaborators

  • Arena Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Arena CT.gov Administrator · Arena Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-04
Primary Completion
2020-09-09
Completion
2021-10-11
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04162769 on ClinicalTrials.gov